9 Meters Biopharma, Inc. NMTR
We take great care to ensure that the data presented and summarized in this overview for 9 METERS BIOPHARMA, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NMTR
Top Purchases
Top Sells
About NMTR
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
Insider Transactions at NMTR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 21
2023
|
Bethany Sensenig Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,100
-18.14%
|
$9,100
$1.21 P/Share
|
Mar 29
2023
|
Mark A Sirgo Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,885
+8.41%
|
-
|
Mar 29
2023
|
Yehuda Michael Rice Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,885
+50.0%
|
-
|
Mar 29
2023
|
Lorin K Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,885
+39.41%
|
-
|
Mar 29
2023
|
Michael T. Constantino Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,885
+41.95%
|
-
|
Mar 29
2023
|
Samantha Ventimiglia Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,885
+50.0%
|
-
|
Mar 27
2023
|
Bethany Sensenig Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,177
+50.0%
|
-
|
Mar 27
2023
|
John Temperato Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,815
+32.92%
|
-
|
Jul 06
2022
|
John Temperato Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
125,000
+8.05%
|
$0
$0.23 P/Share
|
Jul 01
2022
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
175,000
+10.74%
|
$0
$0.25 P/Share
|
May 23
2022
|
Michael T. Constantino Director |
BUY
Open market or private purchase
|
Direct |
16,000
+20.91%
|
$0
$0.48 P/Share
|
May 18
2022
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
106,383
+7.13%
|
$0
$0.47 P/Share
|
May 18
2022
|
John Temperato Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+3.7%
|
$0
$0.45 P/Share
|
Mar 03
2022
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
86,449
+6.33%
|
$0
$0.58 P/Share
|
Mar 03
2022
|
John Temperato Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+7.39%
|
$0
$0.56 P/Share
|
Dec 02
2021
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
50,000
+3.87%
|
$0
$0.89 P/Share
|
Nov 18
2021
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
20,000
+1.65%
|
$20,000
$1.06 P/Share
|
Nov 18
2021
|
John Temperato Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+4.16%
|
$50,000
$1.05 P/Share
|
Sep 14
2021
|
Edward J Sitar Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+7.17%
|
$15,000
$1.22 P/Share
|
Sep 07
2021
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
73,529
+5.9%
|
$73,529
$1.36 P/Share
|